U.S. markets open in 2 hours 15 minutes
  • S&P Futures

    -53.75 (-1.41%)
  • Dow Futures

    -366.00 (-1.18%)
  • Nasdaq Futures

    -196.00 (-1.68%)
  • Russell 2000 Futures

    -27.90 (-1.62%)
  • Crude Oil

    -0.89 (-0.81%)
  • Gold

    -6.20 (-0.34%)
  • Silver

    -0.34 (-1.63%)

    -0.0036 (-0.34%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +1.43 (+5.04%)

    -0.0014 (-0.11%)

    -0.2500 (-0.18%)

    -956.38 (-4.78%)
  • CMC Crypto 200

    -31.50 (-7.17%)
  • FTSE 100

    -132.39 (-1.81%)
  • Nikkei 225

    -411.56 (-1.54%)

Amber Specialty Pharmacy Announces Expanded EVUSHELD™ Services

·3 min read

OMAHA, Neb., June 23, 2022--(BUSINESS WIRE)--Amber Specialty Pharmacy announces the launch of expanded EVUSHELD™ services. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for AstraZeneca’s EVUSHELD™ (tixagevimab co-packaged with cilgavimab) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and pediatric individuals (12 years of age and older weighing at least 40 kg).

EVUSHELD™ may be prescribed for individuals who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and

  • Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or

  • For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

This can include transplant recipients, as well as oncology and other immuno-compromised patients. Amber Specialty Pharmacy’s high-touch service model is designed to support prescribers, like transplant programs, oncologists, and others, who may have patients who might be prescribed EVUSHELD™. The pharmacy provides comprehensive services beginning at the moment of referral, through delivery and beyond, to ensure the best possible patient outcomes.

Amber Specialty Pharmacy will offer EVUSHELD™ at its 19 locations throughout the U.S. They can also coordinate delivery and nursing for at-home administration, if needed.

"Throughout the pandemic, Amber Specialty Pharmacy has consistently risen to the occasion to take care of our patients. Through the administration of monoclonal antibodies, we kept our focus on delivering solutions when our patients needed them the most," said Kristin Williams, president of Amber Specialty Pharmacy. "Our expanded EVUSHELD™ services represent our continued commitment to caring for our patients, especially those who have been without therapeutic options that provided adequate immune response."

For more information about Amber Specialty Pharmacy services, call (888) 370-1724, or visit www.amberpharmacy.com. Read more about the pharmacy’s COVID-19 therapy offerings here.

Amber Specialty Pharmacy, a Hy-Vee, Inc. subsidiary, is a pioneer and leader in the specialty pharmacy industry with nearly 25 years of experience providing specialized care for persons with chronic, complex medical conditions. Amber Specialty Pharmacy has built an exceptional reputation by providing personalized support and quality clinical care to patients and families. This comprehensive care approach supports the medical, emotional, financial and administrative needs of patients throughout the United States. Amber Specialty Pharmacy is accredited by the Utilization Review Accreditation Commission (URAC) and the Accreditation Commission for Health Care (ACHC). Amber Specialty Pharmacy headquarters are located in Omaha, Nebraska, with an additional 18 locations throughout the United States and Puerto Rico. Amber Specialty Pharmacy was named the 2020 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005699/en/


Christina Gayman
Asst. Vice President, Communications
(515) 783-6719